Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
about
The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS studyUpdate on Dendritic Cell-Induced Immunological and Clinical Tolerance.Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
P2860
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@ast
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@en
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@nl
type
label
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@ast
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@en
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@nl
prefLabel
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@ast
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@en
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@nl
P2860
P921
P1476
Efficacy and safety of subcuta ...... and early multiple sclerosis.
@en
P2093
Mark S Freedman
P2860
P304
P356
10.1517/14712598.2014.924496
P407
P5008
P577
2014-06-26T00:00:00Z
2014-08-01T00:00:00Z